Press Release
medac GmbH: New Management structure
medac is a future-oriented company and has been growing dynamically since fifty years. More than 2000 medac employees work on the first-time development and further refinement of pharmaceuticals and medical products for the diagnosis and treatment of oncological, urological and auto-immune diseases. Especially when it is a question of niche products we are one of the leading pharmaceutical companies. We represent solid values and basically think in human terms. This results in long-lasting business partnership relations with clinics, doctors and laboratories, as well as providing a healthy working atmosphere for all our employees
The experimental use of BCG-medac as a vaccine against COVID-19 is associated with a high risk of serious adverse reactions and should therefore be strictly avoided. The Federal Institute for Vaccines and Biomedical Medicines (Paul-Ehrlich Institut (PEI)) has published a respective safety information: